Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127450621 | 12745062 | 1 | I | 20110130 | 20110607 | 20160915 | 20160915 | EXP | US-ROCHE-785063 | ROCHE | 62.41 | YR | M | Y | 74.70000 | KG | 20160915 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127450621 | 12745062 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 28 DAYS; OVER 30-90 MINUTES ON DAY 1 AND 15. LAST DOSE PRIOR TO SAE 27 JANUARY 2011?DATE OF LA | 125085 | 10 | MG/KG | SOLUTION FOR INFUSION | |||||||
127450621 | 12745062 | 2 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE 28 DAYS; ON DAYS 1, 8, 15 AND 22.?DATE OF LAST TREATMENT: 23/MAY/2013 | 0 | 25 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127450621 | 12745062 | 1 | Carcinoid tumour |
127450621 | 12745062 | 2 | Carcinoid tumour |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127450621 | 12745062 | OT |
127450621 | 12745062 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127450621 | 12745062 | Abdominal pain | |
127450621 | 12745062 | Ascites | |
127450621 | 12745062 | Hypertension | |
127450621 | 12745062 | Pulmonary haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |